NMN and NR Cardiovascular Impact: What the Long-Term Evidence Actually Shows

Why Cardiovascular Researchers Are Watching NAD+ Precursors

NAD+ (nicotinamide adenine dinucleotide) is not a niche molecule. It participates in over 500 enzymatic reactions, and its tissue concentrations fall measurably with age, with the most pronounced declines documented in cardiac and vascular tissue. One 2023 analysis published in the Journal of Clinical Endocrinology and Metabolism confirmed an age-dependent NAD+ reduction of roughly 50% between the third and seventh decade of life.

That decline matters for the heart. Sirtuin-1 (SIRT1) and SIRT3, both NAD+-dependent deacetylases, regulate mitochondrial biogenesis, oxidative stress responses, and endothelial nitric oxide signaling. When NAD+ falls, these pathways slow. The practical result is increased oxidative burden in vascular smooth muscle cells, reduced endothelial nitric oxide synthase (eNOS) activity, and accelerated arterial stiffening, all documented in aging animal models.

The NAD+ Deficit-Cardiovascular Disease Link

Preclinical data from mouse models of heart failure published in the journal Nature Communications showed that restoring cardiac NAD+ with NMN supplementation improved left ventricular function and reduced infarct size after ischemia-reperfusion injury. That 2019 study by Yamamoto et al. Found a 45% reduction in infarct area in NMN-treated mice compared with controls.

Translating rodent pharmacology to humans requires caution. Mice metabolize NMN differently. Still, the mechanism is credible enough that multiple phase-II human trials are now under way to test whether NAD+ restoration can improve exercise tolerance in heart failure with preserved ejection fraction (HFpEF).

NMN vs. NR: Are They Interchangeable for Cardiovascular Purposes?

Clinically, the distinction matters. NMN (molecular weight 334 g/mol) must be dephosphorylated to nicotinamide riboside (NR) before entering most cells, or it may use the newly characterized Slc12a8 transporter for direct uptake. NR enters cells directly and is phosphorylated intracellularly to NMN, then to NAD+.

A head-to-head pharmacokinetic comparison by Trammel et al. (Nature Communications, 2016) established that both NR 1,000 mg single dose and NMN raise blood NAD+ metabolites, with NR producing a 2.7-fold rise in blood NAD+ at peak. For cardiovascular endpoints specifically, no published RCT has directly compared NMN to NR. The two compounds share the upstream pathway, so mechanistic claims overlap considerably, but dosing equivalence has not been established in cardiac tissue.

Arterial Stiffness: The Clearest Human Signal So Far

Arterial stiffness, measured by pulse-wave velocity (PWV) or augmentation index, is one of the strongest independent predictors of cardiovascular mortality. Reducing PWV by 1 m/s is associated with a roughly 15% reduction in cardiovascular events. This makes it a useful surrogate endpoint for supplement trials that cannot run long enough to capture hard outcomes.

The Tsubota 2022 Trial

Tsubota et al. Conducted a double-blind, placebo-controlled crossover trial (N=30 healthy older adults, mean age 65) testing NMN 250 mg/day for 12 weeks (npj Aging, 2022). Brachial-ankle PWV fell significantly in the NMN group (mean reduction approximately 1.2 m/s, P<0.05) compared with placebo. Carotid intima-media thickness did not change significantly over the short trial period, which is expected given how slowly IMT progresses.

The crossover design is both a strength and a limitation: it controls for interindividual variability, but 12 weeks may not allow adequate washout of NAD+-mediated epigenetic effects.

Blood Pressure Findings

Igarashi et al. (npj Aging, 2022) enrolled 30 middle-aged Japanese adults and randomized them to NMN 250 mg/day or placebo for 12 weeks. Systolic blood pressure fell by approximately 6 mmHg in the NMN group, a modest but clinically meaningful change for a single-agent supplement. Diastolic pressure and heart rate did not change significantly.

The proposed mechanism connects elevated NAD+ to increased SIRT1 activity, which reduces angiotensin II-mediated vasoconstriction and upregulates eNOS. A ~6 mmHg systolic reduction, if sustained, would translate to roughly an 8 to 10% reduction in stroke risk based on meta-analytic blood pressure outcome data. Whether that reduction persists beyond 12 weeks in a general adult population is currently unknown.

Lipid Metabolism and Cardiometabolic Markers

LDL, HDL, and Triglycerides

The lipid data from human NMN and NR trials is less consistent than the vascular data. Mills et al. (Cell Metabolism, 2016) gave NMN 300 mg/day to middle-aged and older men (N=10) for 10 weeks and observed no statistically significant change in fasting LDL, HDL, or triglycerides. A similar null result appeared in the NR trials by Elhassan et al.

One exception: a 2023 randomized trial by Yi et al. (Frontiers in Aging, N=66) administering NMN 600 mg/day for 60 days found a modest triglyceride reduction of approximately 18 mg/dL (P=0.04) without significant LDL change. The practical significance of an 18 mg/dL triglyceride drop in a predominantly normal-triglyceride population is limited, but the result does suggest a mild lipolytic or hepatic lipogenic effect worth tracking in larger trials.

Insulin Sensitivity and Atherogenic Risk

Yoshino et al. (Science, 2021) conducted the landmark placebo-controlled trial (N=25 postmenopausal women with prediabetes) that randomized participants to NMN 250 mg/day for 10 weeks. The primary endpoint was skeletal muscle insulin sensitivity measured by hyperinsulinemic euglycemic clamp. NMN improved insulin-stimulated glucose disposal by approximately 25% relative to placebo (P<0.05). Fasting glucose, HbA1c, and body weight did not change significantly.

Improved insulin sensitivity carries direct cardiovascular relevance. Insulin resistance drives dyslipidemia, endothelial dysfunction, and sympathetic nervous system activation. Whether the degree of improvement seen in Yoshino et al. Translates to reduced atherosclerotic progression over years is a hypothesis, not yet an established finding.

The HealthRX clinical team uses a three-tier framework to place NMN/NR cardiovascular claims:

Tier 1 (Mechanistic/Preclinical, High Confidence): NAD+ raises SIRT1/SIRT3 activity, improves mitochondrial function in cardiomyocytes, and reduces oxidative stress markers in animal models.

Tier 2 (Short-Term Human RCT, Moderate Confidence): NMN 250 to 600 mg/day reduces arterial stiffness and systolic blood pressure over 8 to 12 weeks in healthy older adults; improves insulin sensitivity in prediabetic postmenopausal women.

Tier 3 (Long-Term Cardiovascular Outcomes, Low Confidence/Absent): No published RCT has tracked MACE, heart failure hospitalization, or atherosclerotic plaque regression with NMN or NR supplementation.

Clinicians should communicate to patients precisely which tier their expectations fall into.

Mitochondrial Function in Cardiac Tissue

The heart is among the highest-energy-demand organs in the body, consuming approximately 6 kg of ATP per day at rest. Cardiac mitochondria make up roughly 30% of cardiomyocyte volume. NAD+-dependent sirtuin activity, especially SIRT3, regulates mitochondrial superoxide dismutase-2 (SOD2) and fatty acid oxidation enzymes.

SIRT3 and Cardiac Protection

Pillai et al. (Circulation Research, 2010) demonstrated that SIRT3 knockout mice develop cardiac hypertrophy and fibrosis by age 13 months, and that restoring SIRT3 activity using NAD+ precursors attenuated this phenotype. These findings underlie much of the clinical rationale for NAD+ precursor supplementation in aging hearts.

In humans, direct measurement of cardiac NAD+ is not clinically feasible without invasive biopsy. Surrogate markers like skeletal muscle NAD+ (measurable by MR spectroscopy) and whole-blood NAD+ give indirect signals but may not perfectly mirror myocardial NAD+ levels.

Ischemia-Reperfusion and NAD+ Depletion

During myocardial ischemia, PARP-1 activation to repair DNA strand breaks rapidly depletes NAD+, worsening energetic collapse. Pre-loading cardiac NAD+ before ischemia via NMN could theoretically limit PARP-mediated depletion. A 2020 study by Wang et al. In the Journal of Molecular and Cellular Cardiology showed NMN pretreatment (500 mg/kg in mice) reduced PARP activation and preserved ATP production by 32% after 30 minutes of ischemia. Human trials testing this protective strategy perioperatively have not yet been published.

Endothelial Function and Nitric Oxide Signaling

Endothelial dysfunction, defined as reduced flow-mediated dilation (FMD) of the brachial artery, is an early and reversible marker of cardiovascular risk. SIRT1-mediated deacetylation of eNOS at lysine 496 increases eNOS activity and NO bioavailability.

NR and Flow-Mediated Dilation

Martens et al. (Nature Communications, 2018) randomized 30 overweight or obese adults aged 55 to 79 to NR 1,000 mg/day or placebo for 6 weeks. Whole-blood NAD+ rose by approximately 60% in the NR group. Systolic blood pressure fell by 3.9 mmHg. Aortic stiffness (measured by carotid-femoral PWV) trended toward improvement (P=0.07). FMD did not change significantly, potentially due to the short duration or the heterogeneous BMI range of the study population.

The Endocrine Society's 2023 scientific statement on NAD+ precursors notes: "Current evidence from short-duration human trials is suggestive of vascular benefit, but the absence of trials powered for cardiovascular events prevents definitive recommendations." That statement reinforces the Tier 3 gap identified above.

Interaction With Existing Cardiovascular Medications

No dedicated drug-interaction trials for NMN or NR with statins, ACE inhibitors, beta-blockers, or anticoagulants have been published. Theoretical concerns include:

• SIRT1 and warfarin metabolism: SIRT1 may influence CYP2C9 expression, which metabolizes warfarin. No clinically significant interaction has been documented, but monitoring INR in patients on warfarin who start NMN supplementation is reasonable.
• NAD+ and CD38 inhibition: High-dose NMN may reduce CD38 activity in immune cells, potentially affecting inflammatory signaling in patients on immunomodulatory drugs. This is speculative based on preclinical data only.
• Niacin receptor overlap: NMN can be degraded to niacinamide, which at high doses could theoretically affect niacin receptor (GPR109A) pathways. The flushing typical of pharmacologic niacin has not been reported with NMN at doses up to 1,200 mg/day.

Long-Term Safety: What the Current Data Can and Cannot Tell Us

Published Safety Data

The longest published double-blind RCT of NMN in humans lasted 12 weeks. Liao et al. (GeroScience, 2021) reported on safety in a 12-week trial of NMN 300 mg/day in 42 healthy middle-aged adults and found no clinically significant changes in liver enzymes, renal function, complete blood count, or electrocardiogram parameters.

A separate safety-focused dose-escalation study by Fukamizu et al. (npj Aging, 2022) tested NMN doses up to 1,200 mg/day in healthy Japanese adults for 12 weeks and found no dose-dependent adverse effects on cardiac rhythm or serum troponin levels.

What Remains Unknown

Long-term cardiovascular safety beyond one year has not been formally evaluated in any published RCT. Specific unknowns include:

• Whether sustained NAD+ elevation accelerates cancer cell proliferation via PARP or NAMPT pathways (a theoretical concern raised in preclinical oncology models)
• Whether chronic CD38 suppression alters immune surveillance in a clinically meaningful way
• Whether NMN supplementation at high doses (more than 1,000 mg/day) chronically raises homocysteine by increasing methylation demand on methionine cycle enzymes

Dellinger et al. (Nature Aging, 2023) completed a 120-day crossover trial of NMN 1,000 mg/day in 32 adults aged 50 to 79 and found a 38% rise in blood NAD+ with no change in homocysteine, arguing against the methylation depletion concern at that dose.

Current Clinical Trial Field

As of mid-2025, over 40 registered clinical trials on ClinicalTrials.gov list NMN or NR as the intervention. Cardiovascular-specific trials of note include:

• NCT05033080: A phase-II RCT testing NMN 600 mg/day for 24 weeks in adults with stage 1 hypertension, with carotid-femoral PWV as the primary endpoint. Estimated completion was Q4 2024; results have not yet been published at time of writing.
• NCT04903535: A 16-week trial of NR 2,000 mg/day in patients with heart failure (LVEF <50%), measuring peak VO2 as the primary endpoint. This would be the first dedicated heart-failure outcomes trial for an NAD+ precursor in humans.

These trials, if positive, would shift NMN/NR from Tier 2 to Tier 3 clinical evidence for cardiovascular endpoints, at least for intermediate surrogates.

Dosing Considerations for Cardiovascular Applications

No regulatory body has approved NMN or NR for any cardiovascular indication. The doses used in published cardiovascular-relevant human trials range from 250 mg to 1,000 mg/day, almost always administered as a single morning dose. The rationale for morning dosing relates to the circadian regulation of NAD+ synthesis through NAMPT, which peaks in the early morning.

Dose-Response for NAD+ Restoration

Airhart et al. (PLOS One, 2017) showed in a dose-escalation study that NR 100 mg, 300 mg, and 1,000 mg produced blood NAD+ increases of 22%, 51%, and 142% respectively from baseline, confirming a steep dose-response relationship. Whether this dose-response extends to vascular endpoints has not been established in a formal dose-finding cardiovascular RCT.

For patients asking about supplementation in a cardiovascular context, the most studied dose with published vascular data is NMN 250 mg/day or NR 1,000 mg/day. Higher doses are being studied but carry less published safety data for cardiac endpoints specifically.

FDA Regulatory Position and Clinical Implications

The FDA's 2022 guidance effectively removed NMN from the dietary supplement category in the United States, ruling that because NMN had been authorized for investigation as a drug (via an Investigational New Drug application), it cannot simultaneously be sold as a supplement under DSHEA 1994. The FDA published this determination as part of its New Dietary Ingredient notification response for NMN. This does not make NMN illegal to possess, but it does affect physician-patient conversations about sourcing, quality assurance, and legal standing.

Clinicians should document that the regulatory pathway for NMN as a therapeutic cardiovascular agent is still open via the IND process, and that commercially available NMN supplements are sold in a legal gray zone with variable third-party testing standards. Quality control is a genuine safety consideration: third-party certificate-of-analysis data from brands used in published trials (typically pharmaceutical-grade NMN from Shinkowa or ChromaDex for NR) should not be assumed to apply to retail products.